Barclays’s Axsome Therapeutics AXSM Stock Holding History

Barclays’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-27,500	Closed	-$2.19M	–	4868
2024 Q1	$2.19M	Sell	27,500 -24,500	-47%	-$2.06M	﹤0.01%	2480
2023 Q4	$4.14M	Buy	+52,000	New	+$3.48M	﹤0.01%	2274
2020 Q2	–	Sell	-201,500	Closed	-$11.9M	–	5564
2020 Q1	$11.9M	Buy	201,500 +136,600	+210%	+$11.1M	0.01%	902
2019 Q4	$6.71M	Buy	64,900 +45,000	+226%	+$1.82M	﹤0.01%	1733
2019 Q3	$403K	Sell	19,900 -39,400	-66%	-$1.01M	﹤0.01%	4415
2019 Q2	$1.53M	Sell	59,300 -37,800	-39%	-$758K	﹤0.01%	3220
2019 Q1	$1.38M	Buy	+97,100	New	+$902K	﹤0.01%	3035

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Barclays's AXSM Position: Q2 2026 in Review

Barclays increased its Axsome Therapeutics (AXSM) stake by 49% in Q2 2026, buying an estimated $3.67M and bringing the position to 51,203 shares worth $12.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1370.

Barclays first reported a position in AXSM in Q3 2016 and has held it in 33 quarters since. The position peaked at $17.6M in Q1 2024. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

Barclays held 51,203 shares of Axsome Therapeutics worth $12.5M as of Q2 2026.
Barclays bought 16,942 Axsome Therapeutics shares in Q2 2026, an estimated $3.67M.
Axsome Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #1370 holding.
Barclays first reported a position in Axsome Therapeutics in Q3 2016 and has held it in 33 quarters since.
Barclays's Axsome Therapeutics position peaked at $17.6M in Q1 2024.
506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.